We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Argenta Delivers Preclinical Candidate for Wellcome Trust Funded Anti-Aging Project

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Delivers Preclinical Candidate for Wellcome Trust Funded Anti-Aging Project"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Argenta, a service division of Galapagos NV has announced that it recently concluded contract research support to the University of Edinburgh for a Wellcome Trust funded Seeding Drug Discovery Initiative (SDDI) project resulting in the successful identification of a preclinical candidate.

The three-year project aimed at identifying selective inhibitors of the 11beta-HSD1 enzyme resulted in the identification of a lead candidate. The class of compounds, which will hopefully enter human clinical trials next year, is being investigated as a potential drug that could slow the natural decline in memory associated with aging. The preclinical candidate has been shown to improve cognitive and memory function in aging mice. The nomination of this preclinical candidate brings the total number of such candidates identified by Argenta in its 10 year history to over 35.